MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

(2010) Vijay Ramakrishnan et al.   AMERICAN JOURNAL OF HEMATOLOGY

De novo Discovery of a  -Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

(2009) J. W. Watters et al.   CANCER RESEARCH

Inhibition of NOTCH Signaling by Gamma Secretase Inhibitor Engages the RB Pathway and Elicits Cell Cycle Exit in T-Cell Acute Lymphoblastic Leukemia Cells

(2009) S. S. Rao et al.   CANCER RESEARCH

Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

(2009) Chelsea C. Pinnix et al.   CANCER RESEARCH

Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma

(2009) Suk-young Lee et al.   CANCER SCIENCE

Notch Signaling: The Core Pathway and Its Posttranslational Regulation

(2009) Mark E. Fortini   DEVELOPMENTAL CELL

Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma

(2009) Ruben Plentz et al.   GASTROENTEROLOGY

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

(2009) V Ramakrishnan et al.   ONCOGENE

Notch Signaling in Leukemia

(2008) Jon C. Aster et al.   Annual Review of Pathology-Mechanisms of Disease

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation

(2008) R Schwarzer et al.   LEUKEMIA

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA